Desensitization to lenalidomide in a patient with relapsed multiple myeloma.


Introduction Lenalidomide belongs to a class of immunomodulatory drugs that represents a promising advancement in the treatment of multiple myeloma (MM). An oral structural analogue of thalidomide, lenalidoide was developed to produce an agent with a more favorable toxicity rofile than that of its parent drug. Initially approved in 2005 for the reatment of… (More)
DOI: 10.1016/j.clml.2012.09.003


1 Figure or Table